An anonymous director reports

SPECTRAL MEDICAL INC. ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

Spectral Medical Inc. has released the results of its annual meeting of shareholders held on June 5, 2025. The company confirms that all resolutions in the management information circular dated April 17, 2025, were approved by shareholders at the meeting.

Results of the matters voted on at the meeting are set out herein.

Appointment of auditor

MNP LLP was reappointed as auditor of Spectral.

Votes for:  99.95 per cent

Votes withheld:  0.05 per cent

About Spectral Medical Inc.

Spectral is a phase 3 company seeking United States Food and Drug Administration approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the company's FDA-cleared Endotoxin Activity Assay (EAA), the clinically available test for endotoxin in blood.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively over 360,000 times to date. In March, 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November, 2010, signed an exclusive distribution agreement for this product in Canada. In July, 2022, the U.S. FDA granted breakthrough device designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

The Tigris trial is a confirmatory study of PMX in addition to standard care versus standard care alone, and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis.

The trial methods are detailed in "Bayesian methods: a potential path forward for sepsis trials."

We seek Safe Harbor.